Directly observed treatment for tuberculosis
- 9 October 2003
- Vol. 327 (7419), 823-824
- https://doi.org/10.1136/bmj.327.7419.823
Abstract
Less faith, more science would be helpful Drugs cure tuberculosis. So why does the disease remain in the top 10 causes of global mortality, with 1.8 million deaths a year?1 Most deaths are in low and middle income countries, where a major challenge is to ensure that drugs are available and people complete the long treatment. The World Health Organization has been tackling the global problem of inadequate tuberculosis control for some years and launched a new programme of integrated care in 1994, called directly observed treatment, short course (DOTS).2 By using a six month course of drugs, including rifampicin, WHO has mobilised money, people, and systems in countries to tackle the global problem with good progress.3 Its strategy is divided into five key aspects: political commitment, access to sputum microscopy, short course chemotherapy using direct observation …Keywords
This publication has 8 references indexed in Scilit:
- Tuberculosis control: past 10 years and future progressTuberculosis, 2003
- Directly observed therapy for treating tuberculosisPublished by Wiley ,2003
- Costs and cost-effectiveness of different DOT strategies for the treatment of tuberculosis in PakistanHealth Policy and Planning, 2002
- Evolution of WHO policies for tuberculosis control, 1948–2001The Lancet, 2002
- Interventions to reduce tuberculosis mortality and transmission in low- and middle-income countries.2002
- Directly observed therapy and treatment adherenceThe Lancet, 2000
- Prospects for worldwide tuberculosis control under the WHO DOTS strategyThe Lancet, 1998
- Directly Observed Therapy for Treatment Completion of Pulmonary TuberculosisConsensus Statement of the Public Health Tuberculosis Guidelines PanelJAMA, 1998